IRIS Accounts Production v24.2.0.383 04646965 Board of Directors 1.4.23 31.3.24 31.3.24 false true false false false true false Ordinary 1.00000 Ordinary B 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh046469652023-03-31046469652024-03-31046469652023-04-012024-03-31046469652022-03-31046469652022-04-012023-03-31046469652023-03-3104646965ns15:EnglandWales2023-04-012024-03-3104646965ns14:PoundSterling2023-04-012024-03-3104646965ns10:Director12023-04-012024-03-3104646965ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3104646965ns10:SmallEntities2023-04-012024-03-3104646965ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3104646965ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3104646965ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3104646965ns10:FullAccounts2023-04-012024-03-310464696512023-04-012024-03-3104646965ns10:OrdinaryShareClass12023-04-012024-03-3104646965ns10:OrdinaryShareClass22023-04-012024-03-3104646965ns10:Director22023-04-012024-03-3104646965ns10:Director32023-04-012024-03-3104646965ns10:RegisteredOffice2023-04-012024-03-3104646965ns5:CurrentFinancialInstruments2024-03-3104646965ns5:CurrentFinancialInstruments2023-03-3104646965ns5:ShareCapital2024-03-3104646965ns5:ShareCapital2023-03-3104646965ns5:RetainedEarningsAccumulatedLosses2024-03-3104646965ns5:RetainedEarningsAccumulatedLosses2023-03-3104646965ns5:NetGoodwill2023-04-012024-03-3104646965ns5:LeaseholdImprovements2023-04-012024-03-3104646965ns5:FurnitureFittings2023-04-012024-03-3104646965ns5:NetGoodwill2023-03-3104646965ns5:NetGoodwill2024-03-3104646965ns5:NetGoodwill2023-03-3104646965ns5:PlantMachinery2023-03-3104646965ns5:PlantMachinery2023-04-012024-03-3104646965ns5:PlantMachinery2024-03-3104646965ns5:PlantMachinery2023-03-3104646965ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-03-3104646965ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-3104646965ns10:OrdinaryShareClass12024-03-3104646965ns10:OrdinaryShareClass22024-03-31
REGISTERED NUMBER: 04646965 (England and Wales)









Unaudited Financial Statements

for the Year Ended 31 March 2024

for

Cellcare Technologies Limited

Cellcare Technologies Limited (Registered number: 04646965)






Contents of the Financial Statements
for the Year Ended 31 March 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Cellcare Technologies Limited

Company Information
for the Year Ended 31 March 2024







DIRECTORS: Mrs K Smith
D J Smith
Ms A Robertson





REGISTERED OFFICE: Unit A2
Harrison Road
Airfield Business Park
Market Harborough
Leicestershire
LE16 7UL





REGISTERED NUMBER: 04646965 (England and Wales)





ACCOUNTANTS: D. K. Rumsby & Co Limited
3 Colwick Quays
Colwick
Nottingham
Nottinghamshire
NG4 2JY

Cellcare Technologies Limited (Registered number: 04646965)

Balance Sheet
31 March 2024

31.3.24 31.3.23
Notes £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 262,432 261,924
262,432 261,924

CURRENT ASSETS
Stocks 34,394 44,226
Debtors 6 412,718 475,731
Cash at bank 1,286,381 1,329,676
1,733,493 1,849,633
CREDITORS
Amounts falling due within one year 7 (360,891 ) (237,177 )
NET CURRENT ASSETS 1,372,602 1,612,456
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,635,034

1,874,380

PROVISIONS FOR LIABILITIES (5,465 ) (2,371 )
NET ASSETS 1,629,569 1,872,009

CAPITAL AND RESERVES
Called up share capital 8 2,000 2,000
Retained earnings 1,627,569 1,870,009
SHAREHOLDERS' FUNDS 1,629,569 1,872,009

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Cellcare Technologies Limited (Registered number: 04646965)

Balance Sheet - continued
31 March 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 20 August 2024 and were signed on its behalf by:





D J Smith - Director


Cellcare Technologies Limited (Registered number: 04646965)

Notes to the Financial Statements
for the Year Ended 31 March 2024

1. STATUTORY INFORMATION

Cellcare Technologies Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2000, is being amortised evenly over its estimated useful life of ten years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Improvements to property - 2% on cost
Fixtures and fittings - 15% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Cellcare Technologies Limited (Registered number: 04646965)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

2. ACCOUNTING POLICIES - continued

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 12 (2023 - 10 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 April 2023
and 31 March 2024 20,000
AMORTISATION
At 1 April 2023
and 31 March 2024 20,000
NET BOOK VALUE
At 31 March 2024 -
At 31 March 2023 -

Cellcare Technologies Limited (Registered number: 04646965)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 April 2023 355,223
Additions 12,892
At 31 March 2024 368,115
DEPRECIATION
At 1 April 2023 93,299
Charge for year 12,384
At 31 March 2024 105,683
NET BOOK VALUE
At 31 March 2024 262,432
At 31 March 2023 261,924

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Trade debtors 356,131 211,571
Other debtors 56,587 264,160
412,718 475,731

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Trade creditors 158,446 49,631
Taxation and social security 73,700 139,053
Other creditors 128,745 48,493
360,891 237,177

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.3.24 31.3.23
value: £    £   
1,800 Ordinary £1 1,800 1,800
200 Ordinary B £1 200 200
2,000 2,000